HC Wainwright Cuts Oncternal Therapeutics (NASDAQ:ONCT) Price Target to $18.00

Oncternal Therapeutics (NASDAQ:ONCT) had its price target reduced by HC Wainwright from $19.00 to $18.00 in a report issued on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, StockNews.com initiated coverage on shares of Oncternal Therapeutics in a research report on Wednesday, August 7th. They set a hold rating on the stock.

Oncternal Therapeutics Stock Up 2.0 %

NASDAQ:ONCT opened at $4.05 on Monday. Oncternal Therapeutics has a 12 month low of $3.81 and a 12 month high of $13.14. The firm has a market cap of $11.99 million, a price-to-earnings ratio of -0.33 and a beta of 1.36. The company’s 50 day moving average is $7.09 and its 200-day moving average is $8.28.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same quarter last year, the firm posted ($3.00) earnings per share. Research analysts predict that Oncternal Therapeutics will post -11.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by hedge funds and other institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.